ExpreS2ion Biotech (EXPRS2) H.C. Andersen Capital Institutional Seminar presentation summary

Market opportunity and unmet need

• Breast cancer is the most common cancer globally, with 2.3 million new cases and 685,000 deaths annually; HER2-expressing tumors account for ~80% of cases, but resistance to current therapies leaves many patients with limited options.

• Incidence is rising in younger women, and by 2040, annual cases may exceed 3 million and deaths may surpass 1 million without new treatments.

• The global breast cancer therapy market is valued at €27B, projected to grow at 7% CAGR over five years, with HER2 drugs showing proven commercial value.

• ES2B-C001's potential peak opportunity is estimated at over €5 billion, with expansion possible into additional HER2-expressing cancers.

Product pipeline and technology

• The company leverages its ExpreS2 platform for multiple immunotherapy projects across cancer and infectious diseases.

• ES2B-C001 is a first-in-class HER2 immunotherapy vaccine targeting the full HER2 extracellular domain, using VLP technology to enhance immunogenicity and induce a broad polyclonal antibody response.

• Preclinical results show strong immune response, tumor growth inhibition, metastasis prevention, and durable effects in resistant models.

• All programs rely on ExpreS2-based manufacturing, often combined with AdaptVac's VLP technology.

Clinical development and milestones

• Phase I clinical trial for ES2B-C001 is underway, with the first three patients dosed and initial immune response data showing HER2-specific antibodies.

• Additional patient data is pending; future milestones include Phase II proof-of-concept in breast cancer and potential expansion to gastric cancer.

• Licensing opportunities may arise after Phase II, with possible conditional approval and registration trials planned.